In vitro evaluation of the effects of potential GSK-3β inhibitors terbutaline and orciprenaline

Yıl 2024, Cilt: 25 Sayı: 1, 73 - 80, 15.04.2024

Ebru Uzunhisarcıklı

https://doi.org/10.23902/trkjnat.1356270

Öz

Lung cancer is a type of cancer that is mostly diagnosed at an advanced stage and has a short survival time despite standard chemotherapy and targeted therapies. Terbutaline and Orci-prenaline are bronchodilator agents that are potent and selective β2 receptor agonists. The purpose of this study was to investigate to evaluate the effects of Terbutaline and Orci-prenaline on A549 human lung carcinoma cell line and Beas-2b human bronchial epithelial cell line. Cells were treated with 1, 10, 100, 200, 400 µM concentrations of Terbutaline and Orciprenaline. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay and xCELLigence real-time cell analyzer were used to determine their effects on cell viability. The cell index was monitored continuously by visualizing the impedance of the E-plate wells. Because of the roles of Glycogen Synthase Kinase 3β (GSK3β) in a diverse range of cellular processes like metabolism, cell proliferation, differentiation and survival and its key position at several signaling pathways, GSK3β inhibition by Terbutaline and Orciprenaline was also investigated. The results showed that Terbutaline and Orciprenaline inhibits GSK-3β. The overall results led to the conclusion that Terbutaline and especially Orciprenaline may have potential therapeutic effects in lung carcinoma.

Anahtar Kelimeler

Lung cancer, Cytotoxicity, Bronchodilator agents, xCELLigence, Glycogen synthase kinase

Etik Beyan

Since the article does not contain any studies with human or animal subject, its approval to the ethics committee was not required.

Destekleyen Kurum

Erciyes University Scientific Research Projects Coordination Unit

Proje Numarası

TLO-2022-12397 and TLO-2022-12398.

Teşekkür

I would like to thank Rukiye Aslan (Kayseri, Türkiye) for her help in the experiments.

Kaynakça

• 1. Alao, J.P., Stavropoulou, A.V., Lam, E.W., Charles Coombes, R. & Vigushin, D.M. 2006. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Molecular cancer, 5: 1-11. https://doi.org/10.1186/1476-4598-5-8
• 2. Barbaros, M.B. & Dikmen, M. 2015. Kanser immünoterapisi. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi, 31(4): 177-182.
• 3. Carter, J. L., Damjanovic, A. K., Molinaro, C. A., Vyas, S., Gridley, D. S., Thyagarajan, S., & Bellinger, D. L. 2006. Sympathetic modulation of mammalian prostate cancer in vitro. Brain, Behavior, and Immunity, 20(3): 8-9. https://doi.org/doi:10.1016/j.bbi.2006.04.016
• 4. Chahl, L.A. & O'Donnell, S.R. 1968. The actions of orciprenaline and protokylol on guinea-pig trachea. British Journal of Pharmacology and Chemotherapy, 33(3): 552. https://doi.org/10.1111/j.1476-5381.1968.tb00504.x
• 5. Cohen, P., Nimmo, H.G. & Proud, C.G. 1978. How does insulin stimulate glycogen synthesis? Biochemical Society Symposium, 43: 69-95.
• 6. DeNicola, L.K., Gayle, M.O. & Blake, K.V. 2001. Drug therapy approaches in the treatment of acute severe asthma in hospitalised children. Paediatric Drugs, 3(7): 509-537. https://doi.org/10.2165/00128072-200103070-00003
• 7. Horáková, K., Šovčı́ková, A., Seemannová, Z., Syrová, D., Bušányová, K., Drobná, Z. & Ferenčı́k, M. 2001. Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants. Free Radical Biology and Medicine, 30(6): 650-664. https://doi.org/10.1016/S0891-5849(00)00508-6
• 8. Inbar, S., Neeman, E., Avraham, R., Benish, M., Rosenne, E., & Ben-Eliyahu, S. 2011. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PloS one, 6(4): e19246. https://doi.org/10.1371/journal.pone.0019246
• 9. Li, J.S., Zhu, M., Tian, D., Wang, M.X., Wang, F., Li, N.P. & Wu, R.L. 2007. Glycogen synthase kinase 3beta induces cell cycle arrest in a cyclin D1-dependent manner in human lung adenocarcinoma cell line A549. Sheng li xue bao: Acta Physiologica Sinica, 59(2): 204-209.
• 10. O’Flaherty, L., Shnyder, S.D., Cooper, P.A., Cross, S.J., Wakefield, J.G., Pardo, O.E. & Tavaré, J.M. 2019. Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer. PLoS One, 14(4): e0214610. https://doi.org/10.1371/journal.pone.0214610
• 11. Parekh, P. & Rao, K.V.K. 2007. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine‐induced progressive liver carcinogenesis. Cell Biology International, 31(1): 35-43. https://doi.org/10.1016/j.cellbi.2006.09.005
• 12. Peng, C., Niu, R., Sun, Q., Cong, B., Zhao, Y., Guo, J. & Zhao, X. 2011. Effects of breathing booster training and inhalation of terbutaline and ambroxol aerosol on pulmonary function in postoperative lung cancer patients. Chinese Journal of Physical Medicine and Rehabilitation, 9: 697-700.
• 13. Schabath, M.B. & Cote, M.L. 2019. Cancer progress and priorities: lung cancer. Cancer Epidemiology, Biomarkers & Prevention, 28(10): 1563-1579. https://doi.org/10.1158/1055-9965.EPI-19-0221
• 14. Shakoori, A., Ougolkov, A., Yu, Z.W., Zhang, B., Modarressi, M.H., Billadeau, D.D. & Minamoto, T. 2005. Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochemical and Biophysical Research Communications, 334(4): 1365-1373. https://doi.org/10.1016/j.bbrc.2005.07.041
• 15. Sultan, K., Zamir, A., Ashraf, W., Imran, I., Saeed, H., Rehman, A.U. & Rasool, M. F. 2023. Clinical pharmacokinetics of terbutaline in humans: a systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(2): 213-227. https://doi.org/ 10.1007/s00210-022-02304-5
• 16. Thapa, R., Gupta, G., Bhat, A.A., Almalki, W.H., Alzarea, S.I., Kazmi, I. & Dua, K. 2023. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies. International Journal of Biological Macromolecules, 253(7): 127375. https://doi.org/10.1016/j.ijbiomac.2023.127375
• 17. Urcan, E., Haertel, U., Styllou, M., Hickel, R., Scherthan, H. & Reichl, F.X. 2010. Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dental Materials, 26(1): 51-58. https://doi.org/10.1016/j.dental.2009.08.007
• 18. Uzunhisarcıklı, E. Yerer, M.B. Neuroprotective Effects of Vapreotide on Tau Transfection–Induced Neurodegeneration. 2022. Neurotoxicity Research, 40(6): 1824-1837. https://doi.org/10.1007/s12640-022-00588-2
• 19. Xu, Y., Wang, J., Wang, X., Zhou, X., Tang, J., Jie, X. & Wu, G. 2022. Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors. Cell Death Discovery, 8(1): 36. https://doi.org/10.1038/s41420-022-00818-8
• 20. Zhou, K., Lai, Y., Wang, Y., Sun, X., Mo, C., Wang, J. & Che, G. 2020. Comprehensive pulmonary rehabilitation is an effective way for better postoperative outcomes in surgical lung cancer patients with risk factors: a propensity score-matched retrospective cohort study. Cancer Management and Research, 12: 8903. https://doi.org/10.2147/CMAR.S267322